Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL751507 | 0.68 | MEN1 (0.33) | MEN1KMT2A | |
| SCHEMBL789751 | 0.67 | — | — | |
| SCHEMBL2225750 | 0.67 | — | — | |
| SCHEMBL10558602 | 0.65 | MEN1 (0.43) | MEN1KMT2A | |
| SCHEMBL351958 | 0.64 | LMNA (0.38) | — | |
| SCHEMBL3289818 | 0.64 | TSHR (0.32) | — | |
| SCHEMBL6772531 | 0.64 | TSHR (0.33) | — | |
| SCHEMBL9894849 | 0.62 | MEN1 (0.61) | MEN1KMT2A | |
| SCHEMBL9901221 | 0.61 | — | — | |
| SCHEMBL1788954 | 0.60 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6469166-B2 | Thiophenopyrimidines | NEUROCRINE BIOSCIENCES, INC. | 2002-10-22 | — | — | US | disclosed |
| US-20020052362-A1 | CRF receptor antagonists; treatment of endocrine, psychiatric and neurologic conditions or illnesses, including stress-related disorders | WEBB THOMAS R (US) | 2002-05-02 | — | — | US | disclosed |
| EP-0882051-B1 | THIOPHENOPYRIMIDINES | JANSSEN PHARMACEUTICA NV (BE) | 2001-11-07 | — | — | EP | disclosed |
| US-6255310-B1 | PSYCHOLOGICAL DISORDERS; ANTIDEPRESSANTS | NEUROCRINE BIOSCIENCES INC. | 2001-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052362-A1 | CRF receptor antagonists; treatment of endocrine, psychiatric and neurologic conditions or illnesses, including stress-related disorders | CRHR1, CRHR2, CRH | MEN1 1940/4885KMT2A 2533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.